Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Ratio (2016 - 2026)

Ironwood Pharmaceuticals' Equity Ratio history spans 16 years, with the latest figure at 0.66 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 23.18% to 0.66 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.66, a 23.18% increase, with the full-year FY2025 number at 0.66, up 23.18% from a year prior.
  • Equity Ratio hit 0.66 in Q4 2025 for Ironwood Pharmaceuticals, up from 0.67 in the prior quarter.
  • Over the last five years, Equity Ratio for IRWD hit a ceiling of 2.88 in Q4 2023 and a floor of 1.02 in Q1 2025.
  • Historically, Equity Ratio has averaged 0.01 across 5 years, with a median of 0.2 in 2021.
  • Biggest five-year swings in Equity Ratio: soared 4380.41% in 2021 and later plummeted 223.1% in 2024.
  • Tracing IRWD's Equity Ratio over 5 years: stood at 0.54 in 2021, then rose by 10.25% to 0.59 in 2022, then surged by 385.3% to 2.88 in 2023, then crashed by 129.85% to 0.86 in 2024, then increased by 23.18% to 0.66 in 2025.
  • Business Quant data shows Equity Ratio for IRWD at 0.66 in Q4 2025, 0.67 in Q3 2025, and 0.9 in Q2 2025.